Roivant Sciences outlines accelerated timelines for key drug developments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 10 2024
0mins
Should l Buy ROIV?
Source: Benzinga
Roivant Sciences Ltd. experienced a price increase of 3.35%, reaching a 52-week high. This movement occurs amid a broader market decline, with the Nasdaq-100 down 1.64% and the S&P 500 down 0.96%.
The surge is attributed to Roivant's announcement of significant progress in its pipeline, particularly highlighting the accelerated timelines for brepocitinib and IMVT-1402. The company plans to file a new drug application for brepocitinib in early 2026, with a potential commercial launch in early 2027. Additionally, advancements in IMVT-1402 were reported, with updated guidance for topline data in rheumatoid arthritis expected in 2026.
This positive news reflects Roivant's strategic focus on its late-stage programs, which could enhance its market position and investor confidence, despite the overall market's downward trend.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ROIV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ROIV
Wall Street analysts forecast ROIV stock price to fall
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 29.700
Low
22.00
Averages
27.63
High
33.00
Current: 29.700
Low
22.00
Averages
27.63
High
33.00
About ROIV
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ROIV Options Contract Analysis and Investment Opportunities
- Put Option Appeal: The current bid for the $27.00 put option is $1.50, meaning if an investor sells this contract, they commit to buying the stock at $27.00, effectively lowering their cost basis to $25.50, which is approximately a 7% discount from the current price of $28.98, making it attractive for those interested in ROIV.
- Yield Potential: Should the put option expire worthless, it would yield a 5.56% return on the cash commitment, or 7.07% annualized, referred to as YieldBoost, highlighting the potential attractiveness of this investment strategy.
- Call Option Returns: The $32.00 call option has a current bid of $2.00; if an investor buys ROIV shares at $28.98 and sells this call, they could achieve a total return of 17.32% if the stock is called away at expiration, indicating high return potential.
- Risk Assessment: Current analytical data suggests a 69% chance that the $27.00 put option will expire worthless, while the $32.00 call option has a 47% chance of expiring worthless, necessitating careful risk consideration for optimizing investment decisions.
See More
BlackBarn Capital Increases Warby Parker Stake by 2 Million Shares
- Stake Increase: BlackBarn Capital increased its stake in Warby Parker by 2 million shares during Q4 2025, with an estimated transaction value of $43.52 million, indicating confidence in the company despite a 15% decline in its stock price over the past year.
- Value Appreciation: The value of Warby Parker's position rose by $37.79 million at quarter-end, reflecting the impact of trading activity and stock price fluctuations, suggesting that BlackBarn Capital's investment strategy is proving effective.
- Asset Allocation Shift: Following the increase, Warby Parker now accounts for 4.3% of BlackBarn Capital's 13F reportable assets, indicating its significance in the investment portfolio, even though it does not rank among the top five holdings.
- Market Performance Insight: As of February 13, 2026, Warby Parker shares were priced at $22.46, underperforming the S&P 500 by 26.8 percentage points, prompting investors to monitor the company's ability to achieve sustainable growth in the optical retail market.
See More
BlackBarn Capital Increases Warby Parker Stake to 3 Million Shares
- Share Increase: According to a recent SEC filing dated February 17, 2026, BlackBarn Capital Partners LP acquired an additional 2 million shares of Warby Parker, raising its total stake to 3 million shares, with an estimated transaction value of $43.52 million, reflecting confidence in the company's growth potential.
- Asset Management Proportion: Warby Parker now accounts for 4.3% of BlackBarn Capital's reportable assets under management, indicating its significance in the firm's 13F report and investor recognition of its potential value.
- Market Performance: As of February 13, 2026, Warby Parker shares were priced at $22.46, down 15% over the past year and underperforming the S&P 500 by 26.8 percentage points, highlighting market concerns regarding its future growth.
- Business Model Analysis: Warby Parker challenges traditional eyewear retail economics through a direct-to-consumer model, and while facing high costs and competitive pressures, its expanding exam capacity may ultimately be key to its future profitability.
See More
Moderna-Arbutus-Genevant Patent Agreement: Wall Street Views It as Suboptimal, Yet Alleviates Pressure on MRNA Shares
Settlement Announcement: Moderna has entered into a $2.25 billion settlement with Arbutus and Genevant regarding a vaccine patent dispute, with a payment of $950 million due in Q3 2026.
Stock Market Reaction: Following the settlement news, Moderna's shares rose by 16%, reflecting a shift in investor sentiment from bearish to bullish.
Future Liabilities: The settlement resolves all enforcement actions against Moderna but leaves a contingent liability of up to $1.3 billion if further litigation affirms liability.
Analyst Insights: Analysts view the settlement as a positive development that alleviates uncertainty for Moderna's stock, while maintaining a neutral rating with a price target of $41.
See More
Moderna Settles for $950 Million with Arbutus, Eyes Future Growth
- Settlement Agreement: Moderna has reached a $950 million settlement with Arbutus Biopharma and Roivant's Genevant Sciences, resolving all litigation related to its COVID-19 vaccine Spikevax and mRESVIA product, which is expected to be paid in the third quarter, significantly alleviating the company's legal burdens.
- Potential Additional Payments: Depending on the outcome of a legal appeal regarding government-contractor immunity, Moderna may face up to $1.3 billion in additional payments, which would represent the largest disclosed patent settlement in the pharmaceutical industry, further impacting the company's financial outlook.
- Future Growth Outlook: CEO Stéphane Bancel emphasized that resolving this legacy issue allows the company to focus on the future, with expectations to end 2026 with $4.5 billion to $5 billion in cash and equivalents, aiming to return to revenue growth in 2026 and achieve breakeven by 2028.
- Positive Market Reaction: The settlement amount was better than feared, leading to an 8.85% increase in Moderna's stock price during Wednesday's premarket trading, currently at $54.24, close to its 52-week high, reflecting investor confidence in the company's future prospects.
See More
Moderna Settles for Up to $2.25 Billion with Arbutus and Genevant
- Settlement Agreement: Moderna has reached a settlement of up to $2.25 billion with Arbutus and Genevant, resolving all enforcement actions related to its COVID-19 vaccine Spikevax and RSV vaccine mRESVIA, ensuring no future royalties and enhancing strategic stability in its infectious disease portfolio.
- Significant Financial Impact: Under the agreement, Moderna will pay $950 million in Q3 2026, with the remaining $1.3 billion contingent on further litigation outcomes, which could significantly affect future cash flows depending on the litigation results.
- Positive Market Reaction: Following the settlement announcement, Moderna's shares surged 11% in after-hours trading, indicating investor optimism about the company's future, while Arbutus shares fell 8%, reflecting market uncertainty regarding its prospects.
- Optimistic Liquidity Outlook: Moderna expects to have $5.4 to $5.9 billion in liquidity by the end of 2026, demonstrating that after resolving legacy issues, the company can focus on future vaccine development and market opportunities, further solidifying its leadership in the biopharmaceutical industry.
See More
ROIV Options Contract Analysis and Investment Opportunities
- Put Option Appeal: The current bid for the $27.00 put option is $1.50, meaning if an investor sells this contract, they commit to buying the stock at $27.00, effectively lowering their cost basis to $25.50, which is approximately a 7% discount from the current price of $28.98, making it attractive for those interested in ROIV.
- Yield Potential: Should the put option expire worthless, it would yield a 5.56% return on the cash commitment, or 7.07% annualized, referred to as YieldBoost, highlighting the potential attractiveness of this investment strategy.
- Call Option Returns: The $32.00 call option has a current bid of $2.00; if an investor buys ROIV shares at $28.98 and sells this call, they could achieve a total return of 17.32% if the stock is called away at expiration, indicating high return potential.
- Risk Assessment: Current analytical data suggests a 69% chance that the $27.00 put option will expire worthless, while the $32.00 call option has a 47% chance of expiring worthless, necessitating careful risk consideration for optimizing investment decisions.
See More
BlackBarn Capital Increases Warby Parker Stake by 2 Million Shares
- Stake Increase: BlackBarn Capital increased its stake in Warby Parker by 2 million shares during Q4 2025, with an estimated transaction value of $43.52 million, indicating confidence in the company despite a 15% decline in its stock price over the past year.
- Value Appreciation: The value of Warby Parker's position rose by $37.79 million at quarter-end, reflecting the impact of trading activity and stock price fluctuations, suggesting that BlackBarn Capital's investment strategy is proving effective.
- Asset Allocation Shift: Following the increase, Warby Parker now accounts for 4.3% of BlackBarn Capital's 13F reportable assets, indicating its significance in the investment portfolio, even though it does not rank among the top five holdings.
- Market Performance Insight: As of February 13, 2026, Warby Parker shares were priced at $22.46, underperforming the S&P 500 by 26.8 percentage points, prompting investors to monitor the company's ability to achieve sustainable growth in the optical retail market.
See More
BlackBarn Capital Increases Warby Parker Stake to 3 Million Shares
- Share Increase: According to a recent SEC filing dated February 17, 2026, BlackBarn Capital Partners LP acquired an additional 2 million shares of Warby Parker, raising its total stake to 3 million shares, with an estimated transaction value of $43.52 million, reflecting confidence in the company's growth potential.
- Asset Management Proportion: Warby Parker now accounts for 4.3% of BlackBarn Capital's reportable assets under management, indicating its significance in the firm's 13F report and investor recognition of its potential value.
- Market Performance: As of February 13, 2026, Warby Parker shares were priced at $22.46, down 15% over the past year and underperforming the S&P 500 by 26.8 percentage points, highlighting market concerns regarding its future growth.
- Business Model Analysis: Warby Parker challenges traditional eyewear retail economics through a direct-to-consumer model, and while facing high costs and competitive pressures, its expanding exam capacity may ultimately be key to its future profitability.
See More
Moderna-Arbutus-Genevant Patent Agreement: Wall Street Views It as Suboptimal, Yet Alleviates Pressure on MRNA Shares
Settlement Announcement: Moderna has entered into a $2.25 billion settlement with Arbutus and Genevant regarding a vaccine patent dispute, with a payment of $950 million due in Q3 2026.
Stock Market Reaction: Following the settlement news, Moderna's shares rose by 16%, reflecting a shift in investor sentiment from bearish to bullish.
Future Liabilities: The settlement resolves all enforcement actions against Moderna but leaves a contingent liability of up to $1.3 billion if further litigation affirms liability.
Analyst Insights: Analysts view the settlement as a positive development that alleviates uncertainty for Moderna's stock, while maintaining a neutral rating with a price target of $41.
See More
Moderna Settles for $950 Million with Arbutus, Eyes Future Growth
- Settlement Agreement: Moderna has reached a $950 million settlement with Arbutus Biopharma and Roivant's Genevant Sciences, resolving all litigation related to its COVID-19 vaccine Spikevax and mRESVIA product, which is expected to be paid in the third quarter, significantly alleviating the company's legal burdens.
- Potential Additional Payments: Depending on the outcome of a legal appeal regarding government-contractor immunity, Moderna may face up to $1.3 billion in additional payments, which would represent the largest disclosed patent settlement in the pharmaceutical industry, further impacting the company's financial outlook.
- Future Growth Outlook: CEO Stéphane Bancel emphasized that resolving this legacy issue allows the company to focus on the future, with expectations to end 2026 with $4.5 billion to $5 billion in cash and equivalents, aiming to return to revenue growth in 2026 and achieve breakeven by 2028.
- Positive Market Reaction: The settlement amount was better than feared, leading to an 8.85% increase in Moderna's stock price during Wednesday's premarket trading, currently at $54.24, close to its 52-week high, reflecting investor confidence in the company's future prospects.
See More
Moderna Settles for Up to $2.25 Billion with Arbutus and Genevant
- Settlement Agreement: Moderna has reached a settlement of up to $2.25 billion with Arbutus and Genevant, resolving all enforcement actions related to its COVID-19 vaccine Spikevax and RSV vaccine mRESVIA, ensuring no future royalties and enhancing strategic stability in its infectious disease portfolio.
- Significant Financial Impact: Under the agreement, Moderna will pay $950 million in Q3 2026, with the remaining $1.3 billion contingent on further litigation outcomes, which could significantly affect future cash flows depending on the litigation results.
- Positive Market Reaction: Following the settlement announcement, Moderna's shares surged 11% in after-hours trading, indicating investor optimism about the company's future, while Arbutus shares fell 8%, reflecting market uncertainty regarding its prospects.
- Optimistic Liquidity Outlook: Moderna expects to have $5.4 to $5.9 billion in liquidity by the end of 2026, demonstrating that after resolving legacy issues, the company can focus on future vaccine development and market opportunities, further solidifying its leadership in the biopharmaceutical industry.
See More
